Function-oriented synthesis, step economy, and drug design

被引:977
作者
Wender, Paul A. [1 ]
Verma, Vishal A. [1 ]
Paxton, Thomas J. [1 ]
Pillow, Thomas H. [1 ]
机构
[1] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
关键词
D O I
10.1021/ar700155p
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This Account provides an overview and examples of function-oriented synthesis (FOS) and its increasingly important role in producing therapeutic leads that can be made in a step-economical fashion. Biologically active natural product leads often suffer from several deficiencies. Many are scarce or difficult to obtain from natural sources. Often, they are highly complex molecules and thus not amenable to a practical synthesis that would impact supply. Most are not optimally suitable for human therapeutic use. The central principle of FOS is that the function of a biologically active lead structure can be recapitulated, tuned, or greatly enhanced with simpler scaffolds designed for ease of synthesis and also synthetic innovation. This approach can provide practical access to new (designed) structures with novel activities while at the same time allowing for synthetic innovation by target design. This FOS approach has been applied to a number of therapeutically important natural product leads, For example, bryostatin is a unique natural product anticancer lead that restores apoptosis in cancer cells, reverses multidrug resistance, and bolsters the immune system. Remarkably, it also improves cognition and memory in animals. We have designed and synthesized simplified analogs of bryostatin that can be made in a practical fashion (pilot scale) and are superior to bryostatin in numerous assays including growth inhibition in a variety of human cancer cell lines and in animal models. Laulimalide is another exciting anticancer lead that stabilizes microtubules, like paclitaxel, but unlike paclitaxel, it is effective against multidrug-resistant cell lines. Laulimalide suffers from availability and stability problems, issues that have been addressed using FOS through the design and synthesis of stable and efficacious laulimalide analogs. Another FOS program has been directed at the design and synthesis of drug delivery systems for enabling or enhancing the uptake of drugs or drug candidates into cells and tissue. We have generated improved transporters that can deliver agents in a superior fashion compared with naturally occurring cell-penetrating peptides and that can be synthesized in a practical and step-economical fashion. The use of FOS has allowed for the translation of exciting, biologically active natural product leads into simplified analogs with superior function. This approach enables the development of synthetically innovative strategies while targeting therapeutically novel structures.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 64 条
  • [21] Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C)
    Marquez, VE
    Blumberg, PM
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) : 434 - 443
  • [22] Exploring chemical space with organometallics: Ruthenium complexes as protein kinase inhibitors
    Meggers, Eric
    Atilla-Gokcumen, G. Ekin
    Bregman, Howard
    Maksimoska, Jasna
    Mulcahy, Seann P.
    Pagano, Nicholas
    Williams, Douglas S.
    [J]. SYNLETT, 2007, (08) : 1177 - 1189
  • [23] Molecular imaging of hydrogen peroxide produced for cell signaling
    Miller, Evan W.
    Tulyanthan, Orapim
    Isacoff, Ehud Y.
    Chang, Christopher J.
    [J]. NATURE CHEMICAL BIOLOGY, 2007, 3 (05) : 263 - 267
  • [24] Polyarginine enters cells more efficiently than other polycationic homopolymers
    Mitchell, DJ
    Kim, DT
    Steinman, L
    Fathman, CG
    Rothbard, JB
    [J]. JOURNAL OF PEPTIDE RESEARCH, 2000, 56 (05): : 318 - 325
  • [25] Microtubule-stabilizing agents based on designed laulimalide analogues
    Mooberry, SL
    Randall-Hlubek, DA
    Leal, RM
    Hegde, SG
    Hubbard, RD
    Zhang, L
    Wender, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) : 8803 - 8808
  • [26] Mooberry SL, 1999, CANCER RES, V59, P653
  • [27] Microtubule-stabilizing marine metabolite laulimalide and its derivatives:: Synthetic approaches and antitumor activity
    Mulzer, J
    Öhler, E
    [J]. CHEMICAL REVIEWS, 2003, 103 (09) : 3753 - 3786
  • [28] Natural products as sources of new drugs over the last 25 years
    Newman, David J.
    Cragg, Gordon M.
    [J]. JOURNAL OF NATURAL PRODUCTS, 2007, 70 (03): : 461 - 477
  • [29] Ohmori K, 2000, ANGEW CHEM INT EDIT, V39, P2290
  • [30] Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model
    Oz, HS
    Hughes, WT
    Rehg, JE
    Thomas, EK
    [J]. MICROBIAL PATHOGENESIS, 2000, 29 (03) : 187 - 190